Editor´s choice articles 2008–2009

• References

• 1 Weimer T, Wormsbächer W, Kronthaler U. et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659-667.
• 2 Metzner HJ, Weimer T, Kronthaler U. et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 634-644.
• 3 Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008; 100: 557-562.
• 4 Nalian A, Lakhiaev AV. Possible mechanisms contributing to oxidative inactivation of activated protein C: Molecular dynamics study. Thromb Haemost 2008; 100: 18-25.
• 5 Nishio M, Koyama T, Nakahara M. et al. Proteasome degradation of protein C and plasmin inhibitor mutants. Thromb Haemost 2008; 100: 405-412.
• 6 Schuepbach RA, Feistritzer C, Fernández JA. et al. Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost 2009; 101: 724-733.
• 7 Bae J-S, Rezaie AR. Thrombin inhibits nuclear factor κB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Thromb Haemost 2009; 101: 513-520.
• 8 Grove EL, Hvas A-M, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
• 9 Busch G, Steppich B, Sibbing D. et al. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost 2009; 101: 340-344.
• 10 Seizer P, Borst O, Langer HF. et al. EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost 2009; 101: 682-686.
• 11 Dellas C, Schäfer K, Rohm I. et al. Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thromb Haemost 2008; 100: 1123-1129.
• 12 Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
• 13 Serebruany V, Shalito I, Kopyleva O. Prasugrel development – claims and achievements. Thromb Haemost 2009; 101: 14-22.
• 14 Distelmaier K, Adlbrecht C, Jakowitsch J. et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102: 564-572.
• 15 Torzewski M, Reifenberg K, Cheng F. et al. No effect of C-reactive protein on early atherosclerosis in LDLR-/- / human C-reactive protein transgenic mice. Thromb Haemost 2008; 99: 196-201.
• 16 Schwarz M, Spath L, Lux CA. et al. Potential protective role of apoprotein J (clusterin) in atherogenesis: Binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity. Thromb Haemost 2008; 100: 110-118.
• 17 Folsom AR, Lutsey PL, Astor BC. et al. C-reactive protein and venous thromboembolism – A prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-619.
• 18 Di Santo S, Tepper OM, von Ballmoos MW. et al. Cell-based therapy facilitates venous thrombus resolution. Thromb Haemost 2009; 101: 460-464.
• 19 Feng Y, vom Hagen F, Wang Y. et al. The absence of angiopoietin-2 leads to abnormal vascular maturation and persistent proliferative retinopathy. Thromb Haemost 2009; 102: 120-130.
• 20 Strijbos MH, Verhoef C, Gratama JW. et al. On the origin of (CD105+) circulating endothelial cells. Thromb Haemost 2009; 102: 347-351.
• 21 Diehl P, Nagy F, Sossong V. et al. Increased levels of circulating microparticles in patients with severe aortic valve stenosis. Thromb Haemost 2008; 99: 711-719.
• 22 Ray DM, Spinelli SL, Pollock SJ. et al. Peroxisome proliferator-activated receptor ? and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost 2008; 99: 86-95.
• 23 Brouckova A, Holada K. Cellular prion protein in blood platelets associates with both lipid rafts and the cytoskeleton. Thromb Haemost 2009; 102: 966-974.
• 24 Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost 2008; 100: 11-13.
• 25 Hughes M, Lip GY. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
• 26 Poli D, Antonucci E, Grifoni E. et al. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 2009; 101: 367-372.
• 27 Rallidis LS, Politou M, Komporozos C. et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99: 1085-1089.
• 28 Ay C, Jungbauer LV, Kaider A. et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. Thromb Haemost 2008; 99: 899-904.
• 29 Levine RL, LeClerc JR, Bailey JE. et al. Venous and arterial thromboembolism in severe sepsis. Thromb Haemost 2008; 99: 892-898.
• 30 Schreijer AJ, Cannegieter SC, Caramella M. et al. Fluid loss does not explain coagulation activation during air travel. Thromb Haemost 2008; 99: 1053-1059.
• 31 Meckley LM, Wittkowsky AK, Rieder MJ. et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100: 229-239.
• 32 Palareti G, Cosmi B. Bleeding with anticoagulation therapy – who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268-278.
• 33 Trujillo-Santos J, Nieto JA, Tiberio G. et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 435-439.